Phosphoinositide 3-kinase p110γ in immunity
Carlotta Costa1, Erica L Martin-Conte, Emilio Hirsch
1Department of Genetic, Biology and Biochemistry and Molecular Biotechnology Center, University of Torino, Via Nizza 52, Torino, Italy.
IUBMB Life
|July 30, 2011
Summary
Phosphoinositide 3-kinase γ (PI3Kγ) is vital for leukocyte inflammatory responses. Targeting PI3Kγ shows promise for developing new anti-inflammatory therapies against various immune diseases.
Area of Science:
- Immunology
- Cell Biology
- Pharmacology
Background:
- Leukocyte response to environmental cues is crucial for immunity.
- Phosphoinositide 3-kinase γ (PI3Kγ) is a key regulator of leukocyte functions.
- PI3Kγ influences leukocyte recruitment and reactive oxygen species production during inflammation.
Purpose of the Study:
- To review recent discoveries on PI3Kγ function in leukocytes.
- To highlight new findings in PI3Kγ-related immune disease models.
- To discuss the therapeutic potential of targeting PI3Kγ.
Main Methods:
- Review of preclinical studies using genetic modification in mice.
- Analysis of pharmacological studies with anti-inflammatory PI3Kγ inhibitors.
- Synthesis of recent research on PI3Kγ in inflammation and immunity.
Main Results:
- PI3Kγ plays a critical role in modulating leukocyte behavior.
- Experimental PI3Kγ inhibitors demonstrate selectivity and specificity.
- Preclinical studies suggest therapeutic applications for PI3Kγ targeting.
Conclusions:
- PI3Kγ is a significant target for anti-inflammatory drug development.
- Targeting PI3Kγ holds potential for treating immune-related diseases.
- Further research continues to uncover novel therapeutic indications for PI3Kγ modulation.
More Related Videos
Related Concept Videos
01:42Phosphoinositides and PIPs
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
01:11IP3/DAG Signaling Pathway
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
01:15Amplifying Signals via Second Messengers
Many receptor binding ligands are hydrophilic; they do not cross the cell membrane but bind to cell-surface receptors. Thus, their message must be relayed by second messengers present in the cell cytoplasm. There are several second messenger pathways, each with its own way of relaying information. For example, the G protein-coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol pathway is active when the receptor induces...